Is Akebia Therapeutics (Akba) a good stock to buy?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09. AKBA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

What are analysts' Akba share price targets?

Their AKBA share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 346.4% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts.

What did Akebia Therapeutics (Akba) do in the first quarter?

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2024.